Implantation and Injectable Dosage Form New Animal Drugs; Imidocarb Dipropionate

Короткий зміст

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for subcutaneous or intramuscular use of imidocarb dipropionate solution for dogs for treatment of babesiosis.